Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACR246 in advanced solid tumors
NCT06238401Phase 1Recruiting
- Sponsor
- Hangzhou Adcoris Biopharmaceuticals
- Start
- Oct 2024
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ACR246 in esophageal cancer, colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and 3 more, sponsored by Hangzhou Adcoris Biopharmaceuticals. Primary endpoint: Safety and Tolerability at 21 days. Started Oct 2024; status: recruiting.
02
Drugs
ACR246
03
Conditions
esophageal cancercolorectal cancer (CRC)non-small cell lung cancer (NSCLC)ovarian cancerprostate cancer (PCa)
Beyond the preview
Go deeper on NCT06238401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06238401.